Abstract:The activation and differentiation of T-cells are mainly directly by their co-regulatory receptors. T lymphocyte-associated protein-4 (CTLA-4) and programed cell death-1 (PD-1) are two of the most important co-regulatory receptors. Binding of PD-1 and CTLA-4 with their corresponding ligands programed cell death-ligand 1 (PD-L1) and B7 on the antigen presenting cells (APC) activates two central co-inhibitory signaling pathways to suppress T cell functions. Interestingly, recent experiments have identified a new cis -interaction between PD-L1 and B7, suggesting that a crosstalk exists between two co-inhibitory receptors and the two pairs of ligand-receptor complexes can undergo dynamic oligomerization. Inspired by these experimental evidences, we developed a coarse-grained model to characterize the assembling of an immune complex consisting of CLTA-4, B7, PD-L1 and PD-1. These four proteins and their interactions form a small network motif. The temporal dynamics and spatial pattern formation of this network was simulated by a diffusion-reaction algorithm. Our simulation method incorporates the membrane confinement of cell surface proteins and geometric arrangement of different binding interfaces between these proteins. A wide range of binding constants was tested for the interactions involved in the network. Interestingly, we show that the CTLA-4/B7 ligand-receptor complexes can first form linear oligomers, while these oligomers further align together into two-dimensional clusters. Similar phenomenon has also been observed in other systems of cell surface proteins. Our test results further indicate that both co-inhibitory signaling pathways activated by B7 and PD-L1 can be down-regulated by the new cis -interaction between these two ligands, consistent with previous experimental evidences. Finally, the simulations also suggest that the dynamic and the spatial properties of the immune complex assembly are highly determined by the energetics of molecular interactions in the network. Our study, therefore, brings new insights to the co-regulatory mechanisms of T cell activation.

CD4 Dimerization and Oligomerization: Implications for T-cell Function and Structure-Based Drug Design

[Several Indirect Methods for Analysis of CD4 Self-Association and Its Function in Stable CD4-MHC-II Binding].

Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

CD4 Function epitope and antagonist: their research advances

Cis Interactions Between CD2 and Its Ligands on T Cells Are Required for T Cell Activation

Crystal Structure Of The Human Cd4 N-Terminal Two-Domain Fragment Complexed To A Class Ii Mhc Molecule

Structural insights into CXCR4 modulation and oligomerization

A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells

The Many Faces of CD4+ T Cells: Immunological and Structural Characteristics

Crystal structure of a complete ternary complex of T-cell receptor, peptide–MHC, and CD4

Lipid-dependent Conformational Dynamics Underlie the Functional Versatility of T-cell Receptor

A Computer Screening Approach to Immunoglobulin Superfamily Structures and Interactions: Discovery of Small Non-Peptidic CD4 Inhibitors As Novel Immunotherapeutics.

Binding symmetry and surface flexibility mediate antibody self-association

Cooperative binding of T cell receptor and CD4 to peptide-MHC enhances antigen sensitivity

Structure, function, and immunomodulation of the CD8 co-receptor

Synthetic Peptides Derived from the Fourth Domain of CD4 Antagonize CD4 Function and Inhibit T Cell Activation

Dynamic Dimerization of Chemokine Receptors and Potential Inhibitory Role of Their Truncated Isoforms Revealed through Combinatorial Prediction

Molecular coordination of αβ T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands

Receptor Dimerization - Rationale for the Design of Bivalent Ligands

Critical residues and motifs for homodimerization of the first transmembrane domain of the plasma membrane glycoprotein CD36